Key terms

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest TMDX news

Apr 03 8:01am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Apr 02 4:55am ET TransMedics management to meet with Oppenheimer Mar 28 9:52am ET Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls Mar 28 5:16am ET TransMedics initiated with an Overweight at Piper Sandler Mar 27 4:26pm ET TransMedics management to meet with Oppenheimer Mar 25 6:25am ET TransMedics Group: Operational Efficiency and Market Positioning Propel Buy Rating Mar 15 10:56am ET TransMedics participates in a conference call with JPMorgan Feb 27 8:30am ET TransMedics price target raised to $102 from $96 at Canaccord Feb 27 7:48am ET Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX) Feb 27 7:38am ET TransMedics price target raised to $105 from $92 at Oppenheimer Feb 27 6:30am ET Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), TransMedics Group (TMDX) and MoonLake Immunotherapeutics (MLTX) Feb 26 4:09pm ET TransMedics sees FY24 revenue $360M-$370M, consensus $330.23M Feb 26 4:09pm ET TransMedics reports Q4 EPS 12, consensus (3c) Feb 07 4:43am ET TransMedics Expands Fleet for National OCS Program Feb 05 4:05pm ET Buy Rating on TransMedics Group Amidst Growing Organ Transplant Market Jan 05 4:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), TransMedics Group (TMDX) and Argenx Se (ARGX)

No recent press releases are available for TMDX

TMDX Financials

1-year income & revenue

Key terms

TMDX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TMDX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms